We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




ALPK3 Truncating Variants Cause Autosomal Dominant Hypertrophic Cardiomyopathy

By LabMedica International staff writers
Posted on 07 Oct 2021
In hypertrophic cardiomyopathy, heart muscles are thicker, which can make it harder for the heart to receive and pump blood. More...
While in most cases the condition will not affect daily life, it can cause heart failure and is frequently cited as the most common cause of sudden unexpected death in young people.

Hypertrophic cardiomyopathy (HCM) is a genetic condition caused by a change or mutation in one or more genes and is passed on through families. A child of someone with HCM has a 50% chance of inheriting the condition. Most people with HCM have no symptoms or feel stable throughout their life. However, others do have symptoms. Some people find that their symptoms worsen in later life. This may be because their heart muscle has slowly become stiffer, making it harder for the heart to pump.

A large team of international scientists led by those at the University College London (London, UK) analyzed the genomes of 2,817 people with hypertrophic cardiomyopathy referred from centers in Spain, the UK, Denmark, Russia, Latvia, Brazil, and Argentina. The discovery cohort comprised 770 consecutively evaluated unrelated patients with HCM. The aim of their study was to determine the frequency of heterozygous truncating alpha-protein kinase (ALPK3) variants (ALPK3tv) in patients with HCM and confirm their pathogenicity using burden testing in independent cohorts and family co-segregation studies.

From 2018 to 2020, ALPK3 was sequenced using next-generation sequencing in 4,904 consecutive unrelated probands with inherited cardiac conditions referred for molecular genetic diagnosis. Coding exons and intronic boundaries of 261 genes related to inherited cardiovascular diseases and sudden cardiac death (SCD) were captured using a custom probe library using the SureSelect Target Enrichment Kit for Illumina paired-end multiplexed sequencing method, (Agilent Technologies, Santa Clara, CA, USA), and sequenced using the HiSeq 1500 platform (Illumina, San Diego, CA, USA).

The investigators reported that in a discovery cohort of 770 index patients with HCM, 12 (1.56%) were heterozygous for ALPK3tv [odds ratio (OR) 16.11) compared to the Genome Aggregation Database (gnomAD) population. In a validation cohort of 2,047 HCM probands, 32 (1.56%) carried heterozygous ALPK3tv (OR 16.17). In comparison with a cohort of 1,679 genotyped patients with HCM with and without pathogenic sarcomere gene variants (SP+ and SP−), ALPK3tv carriers had a higher prevalence of apical/concentric patterns of hypertrophy (60%) and of a short PR interval (10%).

Luis R. Lopes, MD, PhD, a Consultant Cardiologist and the lead author of the study, said, “Hypertrophic cardiomyopathy is an extremely common genetic condition. Earlier, small-scale studies suggested that variants in the ALPK3 gene could be a cause of a rare pediatric form of cardiomyopathy, but only when two abnormal copies were inherited. We have now proved that just one abnormal copy is enough to cause hypertrophic cardiomyopathy in adults, looking at a large number of patients and families. This form of inheritance (autosomal dominant) is much more prevalent, as inheriting just one abnormal copy of a gene is more likely than inheriting two. Identifying a new genetic cause is important as it opens up new possibilities for potential treatment. It also helps families who have been affected by the condition, but who did not know why, to know that a cause has been found for their specific case.” The study was published on August 21 2021 in the European Heart Journal.

Related Links:
University College London
Agilent Technologies
Illumina



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
New
Clinical Chemistry System
P780
New
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The study highlights the potential of cCAFs as a biomarker for early diagnosis and prognosis (H J Woo et al., Analytical Chemistry (2025). DOI: 10.1021/acs.analchem.5c02154)

Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.